AI Article Synopsis

  • Rift Valley fever virus (RVFV) is a serious mosquito-borne pathogen that causes severe health issues in humans and livestock, highlighting the need for effective vaccines.
  • The MP-12 vaccine strain is a live-attenuated version but has limitations in differentiating vaccinated from infected animals (DIVA) due to its functional NSs gene which plays a key role in its virulence.
  • Researchers developed modified MP-12 strains (rMP12-PTNSs and rMP12-SFSNSs) that maintain effectiveness while enabling DIVA, showing promising results in protecting mice and producing neutralizing antibodies comparable to the original MP-12 vaccine.

Article Abstract

Rift Valley fever virus (RVFV; genus Phlebovirus, family Bunyaviridae) is a mosquito-borne zoonotic pathogen which can cause hemorrhagic fever, neurological disorders or blindness in humans, and a high rate of abortion in ruminants. MP-12 strain, a live-attenuated candidate vaccine, is attenuated in the M- and L-segments, but the S-segment retains the virulent phenotype. MP-12 was manufactured as an Investigational New Drug vaccine by using MRC-5 cells and encodes a functional NSs gene, the major virulence factor of RVFV which 1) induces a shutoff of the host transcription, 2) inhibits interferon (IFN)-β promoter activation, and 3) promotes the degradation of dsRNA-dependent protein kinase (PKR). MP-12 lacks a marker for differentiation of infected from vaccinated animals (DIVA). Although MP-12 lacking NSs works for DIVA, it does not replicate efficiently in type-I IFN-competent MRC-5 cells, while the use of type-I IFN-incompetent cells may negatively affect its genetic stability. To generate modified MP-12 vaccine candidates encoding a DIVA marker, while still replicating efficiently in MRC-5 cells, we generated recombinant MP-12 encoding Punta Toro virus Adames strain NSs (rMP12-PTNSs) or Sandfly fever Sicilian virus NSs (rMP12-SFSNSs) in place of MP-12 NSs. We have demonstrated that those recombinant MP-12 viruses inhibit IFN-β mRNA synthesis, yet do not promote the degradation of PKR. The rMP12-PTNSs, but not rMP12-SFSNSs, replicated more efficiently than recombinant MP-12 lacking NSs in MRC-5 cells. Mice vaccinated with rMP12-PTNSs or rMP12-SFSNSs induced neutralizing antibodies at a level equivalent to those vaccinated with MP-12, and were efficiently protected from wild-type RVFV challenge. The rMP12-PTNSs and rMP12-SFSNSs did not induce antibodies cross-reactive to anti-RVFV NSs antibody and are therefore applicable to DIVA. Thus, rMP12-PTNSs is highly efficacious, replicates efficiently in MRC-5 cells, and encodes a DIVA marker, all of which are important for vaccine development for Rift Valley fever.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630143PMC
http://dx.doi.org/10.1371/journal.pntd.0002181DOI Listing

Publication Analysis

Top Keywords

mrc-5 cells
20
rift valley
12
valley fever
12
recombinant mp-12
12
rmp12-ptnss rmp12-sfsnss
12
mp-12
11
fever virus
8
mp-12 strain
8
nss
8
punta toro
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!